Pharma & biotech

Lundbeck to test drug candidate as treatment for Cushing's syndrome

Through this new study, Lundbeck expands its research area to include neurohormonal disorders.
Lundbeck has initiated a Phase II study with the drug candidate Lu AG13909 as a potential treatment for Cushing's syndrome. | Photo: Thomas Borberg/Politiken/Ritzau Scanpix
Lundbeck has initiated a Phase II study with the drug candidate Lu AG13909 as a potential treatment for Cushing's syndrome. | Photo: Thomas Borberg/Politiken/Ritzau Scanpix
af marketwire

Lundbeck has initiated a Phase II study with the drug candidate Lu AG13909 as a potential treatment for Cushing’s syndrome, it announced in a press release on Wednesday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs